Cure model analysis in cancer: An application to data from the Children's Cancer Group

Statistics in Medicine

Volumn 21, Issue 2, 2002, Pages 293-312

  Sposto, Richard ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

Non proportional hazards regression; Paediatric cancer; Parametric survival

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ARTICLE; CANCER STATISTICS; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL RESEARCH; CONTROLLED STUDY; COVARIANCE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; PROGNOSIS; REGRESSION ANALYSIS; STATISTICAL MODEL; TREATMENT FAILURE; TREATMENT OUTCOME;

CHILD; DATA INTERPRETATION, STATISTICAL; DISEASE-FREE SURVIVAL; HODGKIN DISEASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LYMPHOMA, NON-HODGKIN; MODELS, STATISTICAL; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037196195     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.987     Document Type: Article

References (53)

1. Acute lymphoblastic leukaemia in children: Advances and prospectus
2. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: A report of CCG-551 from the Childrens Cancer Group
3. High survival rate in advanced stage Bcell lymphomas and leukaemias without CNS involvement with a short intensive polychemotherapy: Results from the French Pediatric Oncology Society of a randomized trial of 216 children
4. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and 1-asparaginase maintenance Children's Cancer Group Study CCG-5912
5. Response of children with high-risk acute lymphoblastic leukaemia treated with and without cranial irradiation: A report from the Children's Cancer Group
6. Chemotherapy for induction of remission of childhood acute myeloid leukaemia followed by marrow transplantation or multiagent chemotherapy: A report from the Children's Cancer Group
7. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
8. Maximum likelihood estimates of the proportion of patients cured by cancer therapy
9. Survival curves for cancer patients following treatment
10. The estimation of the proportion of patients cured after treatment for cancer of the breast
11. A two-parameter model for the survival curve of treated cancer patients
12. A test of several parametric statistical models for estimating success rate in the treatment of carcinoma cervix uteri
13. Distribution free estimation of cure time
14. The use of mixture models for the analysis of survival data with long-term survivors
15. Survivorship analysis when cure is a possibility: A Monte Carlo study
16. Determining the duration of comparative clinical trials while allowing for cure
17. Mixture models in survival analysis: Are they worth the risk?
18. Cure rate models: Power of the logrank and generalized Wilcoxon tests
19. The cure model and time confounded risk in the analysis of survival and other timed events
20. A comparison of tests of the difference in the proportion of patients who are cured
21. A mixture model combining logistic regression with proportional hazards regression
22. Estimating the proportion of immunes in a censored sample
23. Parametric versus non-parametric methods for estimating cure rates based on censored survival data
24. Exponential mixture-models with long-term survivors and covariates
25. Parametric versus nonparametric methods for estimating cure rates based on censored survival data
26. Parametric versus nonparametric methods for estimating cure rates based on censored survival data - Reply
27. Testing for the presence of immune or cured individuals in censored survival-data
28. Group sequential methods for comparison of cure rates in clinical trials
29. The likelihood ratio test for the presence of immunes in a censored sample
30. Estimating the proportion of immunes in censored samples - A simulation study
31. Nonparametric estimation and testing in a cure model
32. A cure model with time-changing risk factor: An application to the analysis of secondary leukaemia. A report from the International Database on Hodgkin's Disease
33. A generalized F mixture model for cure rate estimation
34. Modelling cure rates using the Gompertz model with covariate information
35. A proportional hazards model taking account of long-term survivors
36. Two-part survival models applied to administrative data for determining rate of and predictors for maternal-child transmission of HIV
37. Mixture models for cancer survival analysis: Application to population-based data with covariates
38. Estimation in a Cox proportional hazards cure model
39. Skin melanoma; cured fraction and survival time as functions of thickness, site, histologic type, age, and sex
40. Squamous carcinoma of the head and neck-cured fraction and median survival-time as functions of age, sex, histologic type, and node status
41. A model of long-term survival following adjuvant therapy for stage 2 breast cancer
42. A stable, multivariate extension of the log-normal survival model
43. Parametric survival analysis of adjuvant therapy for stage II breast cancer
44. The impact of stage and histology on the long-term clinical course of 163,808 patients with breast-carcinoma
45. Threshold models of tumor recurrence
46. Daunomycin plus COMP vs COMP therapy in childhood non-lymphoblastic lymphomas
47. Disseminated nonlymphoblastic lymphoma of childhood: A Childrens Cancer Group study, CCG-552
48. Double delayed intensification improves outcome in moderate risk pediatric acute lymphoblastic leukemia (ALL): A Children's Cancer Group study, CCG-1891
49. Curability of breast cancer
50. Long term survival analysis: The curability of breast cancer